Bob Kronemyer

January 19, 2022

A phase 2, multicenter study has found relugolix (Myfembree; Myovant Sciences) significantly decreases menstrual blood loss in women with uterine leiomyomas and is mostly well tolerated.Relugolix is a small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist.

January 19, 2022

A clinical study has confirmed that the pathophysiology of recurrent vulvovaginal candidiasis (RVVC) relies primarily on Candida albicans (C. albicans)-specific attributes like hyphal morphogenesis, biofilm formation and pathogenesis that differentiate it from other prominent non-albicans C. (NAC) species.

January 19, 2022

Autophagy is a controlled lysosomal degradation pathway that protects cells and allows to overcome cell death.

January 18, 2022

The authors noted that both primary options for treatment are currently being debated as to their efficacy and safety.

January 18, 2022

A case report of infiltrative endometriosis without endometrioma underscores the need to consider endometriosis in the differential for patients with pelvic masses and to recognize possible features that might indicate the diagnosis.

January 18, 2022

Among women with vulvovaginal candidiasis (VVC) or recurrent VVC (RVVC), the 3 most common signs and symptoms are itching (91.2%), burning (68.3%), and redness (58.1%), according to an online patient survey in BMC Womens Health.